Few studies have investigated the efficacy of a short course therapy for patients with favorable predictive factors; most of these studies have used interferon monotherapy4, 5, while others have used a combination treatment for shorter duration in relapsed patients6. There is evidence that combination treatment may be beneficial when used as induction therapy, followed by interferon in a short course program, 7. Cases infected with HCV genotype 3 being treated for as little as 4-12 weeks and remaining sustained responders have been reported8